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Human immunodeficiency virus (HIV) is the etiologic agent of the acquired
immunodeficiency syndrome (AIDS) . The cytolytic infection ofCD4 lymphocytes
by HIV (1, 2) contributes to progressive immunodeficiency. More recently, CD4
monocyte/macrophages have been shown to be infected in vitro (3, 4) and in
vivo (5-10) . These cells may serve as a reservoir for the virus because HIV
replication in monocyte/macrophages appears to be more prolonged and less
cytolytic than in lymphocytes (3, 4, 8) .
The most potent inhibitors of HIV replication yet identified are dideoxynu-
cleosides (11, 12), which include 3'-azido-3'-deoxythymidine (AZT, azidothy-
midine, zidovudine), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxyadenosine
(ddA) . To become active, these drugs are phosphorylated by host cells, and as
5'-triphosphates inhibit the viral reverse transcriptase and/or terminate DNA
chain elongation (13, 14) . AZT has been evaluated in patients with AIDS and
AIDS-related complex (ARC), and has been shown to increase CD4 cell counts,
improve cutaneous delayed hypersensitivity, and reduce the frequency of serious
opportunistic infections ; however, it does not significantly reduce the rate of
recovery of virus from peripheral blood of treated patients . (15-17) . ddC is
under phase I investigation .
Previous studies of dideoxynucleosides in vitro have used either a mixed
population ofhuman peripheral blood mononuclear cells or continuously divid-
ing CD4 cell lines . We now report the activity of these drugs in terminally
differentiated, nondividing, primary human monocyte-derived macrophages
(MDM) . Compared to T lymphoblastoid cells, the MDM were found to have
diminished deoxynucleoside kinase activitiesand reduced ability to phosphorylate
AZT, ddC, or ddA . None of these dideoxynucleosides inhibited the infection or
replication of HIV in macrophages in vitro .
Materials and Methods
Cells. The human T lymphoblastoid cell line, CCRF-CEM, and the human T cell
leukemia virus type 1-transformed human T lymphoblastoid cell line, MT2 (18), were
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obtained and propagated in RPMI 1640 medium containing 100 U/ml penicillin G, 100
pg/ml streptomycin, 2 mM glutamine, and 10% FCS (Hyclone Laboratories, Logan, UT).
Human MDM cultures were obtained from the blood of volunteers who were negative
for antibody to HIV. Mononuclear cells were prepared using isopycnic centrifugation in
ficoll-Hypaque (4).
For infectivity studies, the mononuclear cells were suspended at 106 cells/ml in RPMI
1640 with 2 MM L-glutamine, 50 lsg/ml gentamicin, and 10% autologous serum, and 1 .0
ml was placed in the 1-cm2 wells of a 48-well plate (Costar, Cambridge, MA). After
incubation at 37°C in 5% C02 for 3-7 d, nonadherent cells were removed by gently
washing the monolayers three times with warm media. At this; point the medium was
modified to contain 10% FCS instead of autologous serum. 'Cells prepared by this
technique were at least 95% MDM, asjudged by esterase staining. For nucleoside kinase
and uptake studies, the MDM were separated from peripheral blood lymphocytes by two
cycles of adherence to gelatin-coated flasks (19).
Drugs.
￿
AZT and [8H]AZT were the generous gifts of S. Lehrman, P. Furman, and T.
Krenitsky (Burroughs-Wellcome, Research Triangle Park, NC). ddC and [5H]ddC were
the generous gifts of I . Sim (Hoffman-LaRoche, Nutley, NJ). ddA was purchased from
Sigma Chemical Co. (St. Louis, MO). [8H]ddA was purchased from Moravek Biochemicals,
Brea, CA. The radioactive and unlabelled dideoxynucleosides were mixed to yield a final
specific activity of 1-2 mCi/,umol.
Nucleoside Kinase and Uptake Assays.
￿
For nucleoside kinase assays, cells were washed
at 4°C in isotonic PBS, pH 7.4, and then were frozen and thawed three times. After
centrifugation and desalting on Sephadex G-25, nucleoside kinase activities were measured
radiochemically (20) at a final substrate concentration of 10 UM. The reaction mixtures
contained 10 mM ATP, 10 MM MgC12, 10 mM NaF, and cellular protein (10-40 ug), in
50 mM Tris, pH 8.0. After 10- and 30-min incubations, the nucleotide products were
separated by thin-layer chromatography on polyethyleneimine-cellulose in metha-
nol/water (1 :1). Activities are expressed as picomoles per minute per milligram protein,
determined according to Bradford (21).
For nucleoside uptake studies, cells were suspended at a density of 2 X 106 cells/ml in
RPMI 1640 medium supplemented with 2 MM L-glutamine and either 10% autologous
plasma or serum (for MDM), or 10% FCS (for CEM). The labelled nucleosides (1 '.M, 1 .0
,uCi/ml) were added to the cell suspensions, which were incubated in 17 X 100-mm
polypropylene tubes at 37° C, with occasional shaking. After 4 or 18 h, the cells were
washed three times with PBS until the supernatants were free of radioactivity. Then an
aliquot of ddATP or ddCTP was added as an internal recovery marker. The cell pellets
were extracted with 60% methanol at -20°C overnight. The radioactivity in the solubi-
lized pellets was determined in a liquid scintillation counter. The nucleotides in some of
the samples were fractionated by HPLC (13, 14).
Virus.
￿
The LAV-1 strain of HIV was obtained from Drs. F. Barre-Sinoussi, J .-C.
Chermann, and L. Montagnier (Institut Pasteur, Paris, France). A cell-free virus pool was
prepared in CEM cells and had a titer of 108 TCID5o/ml as assayed by giant cell formation
in MT2 cells.
Antiviral Drug Assays.
￿
Cells were infected at a multiplicity of infection of one tissue
culture 50% infectious dose TCID5o/cell for 60 min at 37° C in medium containing 1%
polybrene. MDM cell monolayers containing ^-105 cells/well in 24-well plates were then
washed three times before incubation in medium containing drug. CEM cells were infected
in suspension at 6 X 106 cells/ml, washed three times by centrifugation and resuspension,
and then distributed in 48-well plates at 6 X 105 cells/well before the addition of medium
containing drug. Antiviral activity was assayed by the inhibition of the production of HIV
p24 (gag) antigen in the cell-free culture medium of infected cells exposed to different
concentrations of drugs. p24 antigen was assayed by ELISA (Abbott Laboratories, Chi-
cago, IL) according to the manufacturer's instructions. The postwash antigen levels were
<100 pg/ml.
Results
Nucleoside Kinase Activities. The nucleoside kinase activities in extracts of
human MDM and CEM T lymphocytes were assessed radiochemically (Table 1).1146
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TABLE I
Nucleoside Kinase Activities
Thymidine Deoxycytidine Uridine Adenosine
kinase kinase kinase kinase
CEMT
￿
36 ± 16
￿
20 t 8
￿
113 f 59
￿
332 t 74 lymphoblasts
MDM 9±4 4±2 13±8 202±78
The nucleoside kinase activities in extracts of CEM T lymphoblasts or
MDM were determined radiochemically at a substrate concentration of
10 uM.Activities areexpressedas picomoles ofnucleotide per minute per
milligram protein (±SEM; n = 3for CEM, n = 4 forMDM).
TABLE II
Nucleoside Phosphorylation by Intact Cells
Cells AZT ddC ddA
CEMT lymphoblasts
￿
17 t 2
￿
2.8 ± 1.6
￿
2.8 ± 0.5
MDM
￿
2±0.8 1.5±0.6 1.6±0.1
Either CEM T lymphoblasts or MDM were incubated for 4 h with I WM
radiolabelled AZT, ddC, or ddA. After washing and extraction, radioac-
tive nucleotide formation was assessed. The results are expressed as
picomolesper 106cells (±SEM; n = 3 for CEM, n = 2 for MDM), and are
corrected forrecoveries of 60-90%.
Compared tothe T lymphoblasts, the MDM had lower levels ofthymidine kinase,
deoxycytidine kinase, and uridine kinase. Adenosine kinase activity was abundant
in both cell types.
Phosphorylation of Dideoxynucleosides.
￿
MDM and CEM cells were compared
for their ability to phosphorylate dideoxynucleosides (Table II). CEM T lympho-
blasts accumulated more of each dideoxynucleotide over a 4-h period than did
MDM. The disparity persisted when the incubations were prolonged to 18 h.
The difference in phosphorylation between Tlymphoblasts and MDM was much
greater for AZT than for either ddC or ddA. HPLC analyses revealed that, in
both cell types, 5'-triphosphates accounted for -10% of AZT nucleotides and
2% of ddC nucleotides.
Inhibition ofHIVReplication by Dideoxynucleosides.
￿
The relativeantiviral effects
ofthe dideoxynucleosides in the CEM CD4 lymphoblastoid cell line and in MDM
cells were compared (Fig. 1). In CEM cells, >50% inhibition of p24 antigen is
observed with 0.1 jM ddC, 1 FiM AZT, or 10 1,M ddA. These resultscorrespond
to those obtained by others in different lymphocyte-derived cell lines or in
stimulated primary human lymphocyte cultures (11, 12). In contrast, little ifany
antiviral activity could be documented in MDM cells with any of these three
drugs, at concentrations as high as 100 tM. Similar results were obtained in nine
separate experiments, and for cells treated with drugs before infection.
Discussion
The CD4 lymphocyte is well-recognized as a critical host cell in the pathogen-
esis of HIV infection. Dideoxynucleosides are phosphorylated by these cells, and
the triphosphate products have potent antiviral activity (11-14). HIV has also
been found to replicate in macrophages. Cells with macrophage markers in theRICHMAN ET AL .
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FIGURE 1 .
￿
Inhibition of p24 antigen production in the
medium of HIV-infected cell cultures exposed to various
concentrations of dideoxynucleosides. HIVantigen levels
were measured in the cell-free medium of cultures 72 h
after infection at a multiplicity of infection of I
TCID5o/cell . Each value was assayed on triplicate wells.
The values for the no-drug control wells were 1,585 ±
135 ng/ml for CEM cells and 1,200 ± 158 pg/ml for
MDM cells.
brains, lungs, and skin of patients with AIDS have been shown to contain
infectious virus, viral antigens, or viral nucleic acid (3-9) . Human MDM cells
can be readily infected in vitro (3, 4) .
In this report, humanMDM wereshown to have lowerdeoxynucleoside kinase
activities than T cells, and to phosphorylate three dideoxynucleosides with anti-
HIV activity (AZT, ddC, and ddA) less efficiently than T lymphocytes. The
MDM permitted HIV replication at dideoxynucleoside concentrations that were
10-1,000-fold higher than those sufficient to block HIV infection ofT lympho-
blasts . AlthoughMDMaccumulated less dideoxynucleoside 5'-triphosphates than
did T lymphoblasts over a 4-h period, the magnitude of the difference cannot
account entirely for the failure of the dideoxynucleosides to inhibit HIV repli-
cation in MDM . Other factors, such as nucleotide pools and the initial rate of
nucleotide formation compared with the time of reverse transcription, may also
influence the anti-HIV activity of the compounds in MDM.
Murine (22, 23) and human (24) macrophages have been reported to lack
thymidine kinase activity . These cells, in fact, release deoxypyrimidines extracel-
lularly, an activity that has been proposed to modulate lymphocyte function (22-
24) . It is not surprising that a cell no longer programmed to synthesize DNA has
reduced requirements for deoxynucleoside salvage. These cells, which are met-
abolically highly active and may survive for prolonged periods, do have high
adenosine kinase activities, consistent with requirements forATP synthesis .
The results ofthese studies may explain what have been confusing observations
made as part of clinical trials of AZT. The treatment of patients with AIDS or
ARC with AZT has resulted in elevation of CD4 peripheral blood cell counts,
restoration of cutaneous delayed hypersensitivity, and reduction in the rate of
opportunistic infections and death (15, 16) . However, AZT had no effect on
virus isolation ratesfrom peripheral blood cells, despitea reduction of circulating1148
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p24 antigen in serum (16). These observations suggest that a subset of infected
cells persists which represent a reservoir ofcontinuing viral replication. Perhaps
the infection ofmacrophages in vivo by HIV cannot be prevented completely by
dideoxynucleosides. This conclusion suggests thatmoreeffective therapyofHIV
infection may require either the delivery of prephosphorylated nucleosides,
perhaps via liposomes, or the identification ofcompounds whoseantiviral activity
is independent ofhost cell metabolism.
Summary
Primary human monocyte-derived macrophages (MDM) were shown to have
diminished deoxynucleoside kinase activities compared to Tlymphoblasts, and a
reduced ability to phosphorylate dideoxynucleosides with anti-human immuno-
deficiency virus (HIV) activity. These drugs, azidothymidine (AZT), dideoxycy-
tidine (ddC), and dideoxyadenosine (ddA), which are potent anti-HIV agents in
CD4 lymphocytes, did not inhibit HIV replication in MDM, even at concentra-
tions of 100 pM. This drug concentration of AZT is ^-100-fold higher than the
levels attained in the serum of treated patients and the levels required to inhibit
HIV replication in lymphocytes. These observations may explain the failure of
AZT therapy to clear viremia, consistent with the presence of a drug-resistant
reservoir of infected cells in vivo. New therapeutic approaches to inhibit the
replication ofHIV in MDM may be needed.
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